Search
Syndax Pharmaceuticals Inc
SNDXAdd to Watchlist
18.070USD
+0.450+2.55%
Close 09-21 16:00（ET）
1.61BMarket Cap
LossP/E TTM
Syndax Pharmaceuticals Inc (SNDX) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Syndax Pharmaceuticals Inc in the past month.
Buy
6 Strong Buy
7 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
39.000USD+121.34%
SNDX Analyst Recommendation Trends
In the current month, SNDX has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SNDX average Analyst price target in the last month is 39.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
6
6
6
6
6
6
6
6
7
7
8
8
8
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
14
14
14
14
14
14
SNDX Analyst Rating for Peer Comparison
Updated: Sep 21, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, SNDX EPS is projected to reach -0.475 in FY2026Q3, following reported EPS of -0.555 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.58
-0.58
-0.44
-0.47
-0.44
Actual
-0.78
-0.48
-0.55
--
--
Surprise
-33.99%
+16.93%
-25.42%
--
--
FAQs
What is Syndax Pharmaceuticals Inc's expected revenue for the next quarter?
Syndax Pharmaceuticals Inc's expected revenue is 82.84M.
What is Syndax Pharmaceuticals Inc's price target?
Analysts forecast that Syndax Pharmaceuticals Inc's price target is USD 39.00, with the highest forecast at USD 57.00 and the lowest forecast at USD 26.00.
How have Syndax Pharmaceuticals IncSNDX's recent earnings per share performed?
The market expectation was USD -0.55, while Syndax Pharmaceuticals IncSNDX's earnings per share (EPS) for the previous quarter was USD -0.48. EPS for the next quarter is expected at USD -0.47.
What is the analyst rating for Syndax Pharmaceuticals Inc?
Based on the ratings of Syndax Pharmaceuticals Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.